Clinical Trial Update: Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31] [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lenalidomide in patients with intermediate-2 or high-risk myelodysplastic syndromes associated with deletion of chromosome 5q.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: UNKNOWN